Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ifosfamide · 1 trial · 7 indications
Overall response rate (CR and PR) after 3 cycles of C R ICE in patients age of 18 to 75 with relapsed/refractory CD20-positive DLBCL treated with rituximab-based immunochemotherapy (e.g., R-CHOP, R-EPOCH, R-HyperCVAD, etc.) induction. Response was based on a Modified Cheson Criteria with Complete response (CR): All lesions with a longest diameter ≤ 15 mm or short axis ≤ 10 mm (Not palpable during the clinical examination, No visible nodule on imaging, And disappearance of all non-nodal target lesions Or in case of hypermetabolic disease on the baseline PET scan, negative PET scan whatever the appearance of lesions on CT) and Partial Response (PR): ≥ 50 % of sum of the products of the diameters (SPD) of target lesions or in the case of hypermetabolic lesions on the baseline PET scan, persistence of at least one PET-positive site without progression of other lesions on CT (≥ 50 % of SPD of target lesions (or longest diameter if a single nodule) No clinically enlarged liver or spleen)
| Arm | Type | Description |
|---|---|---|
| Treatment (carfilzomib, rituximab, chemotherapy) | EXPERIMENTAL | Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Carboplatin | DRUG | Given IV |
| Carfilzomib | DRUG | Given IV |
| Etoposide | DRUG | Given IV |
| Ifosfamide | DRUG | Given IV |
| Laboratory Biomarker Analysis | OTHER | Correlative studies |
| Pharmacological Study | OTHER | Correlative studies |
| Rituximab | BIOLOGICAL | Given IV |
Inclusion Criteria: * Histological confirmation of relapsed/refractory CD20 positive diffuse large B-cell lymphoma * Ann Arbor stage I to stage IV DLBCL at the time of relapsed/refractory disease to be eligible * Measurable or assessable disease is required; measurable tumor size (at least one node...
Ifosfamide is used for CD20 positive diffuse large B-cell lymphoma (DLBCL), specifically in patients with relapsed or refractory stage I-IV disease. It is being studied as part of a combination regimen for this oncology indication.
Ifosfamide is being developed by Amgen Inc., which trades under the ticker AMGN. The company is conducting clinical research on this small molecule for the treatment of CD20 positive diffuse large B-cell lymphoma.
Ifosfamide is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is active but not recruiting participants.
Ifosfamide is being studied in NCT01959698, a Phase 1 trial combining carfilzomib, rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory diffuse large B-cell lymphoma. The trial enrolls 29 participants in the United States.
Ifosfamide is a small molecule used in oncology. Its specific molecular target is not disclosed in the available information, so its mechanism of action is not detailed here.
Ifosfamide is not known to have alternative names in the available information. It is a distinct drug being studied for CD20 positive diffuse large B-cell lymphoma.